PJA2 Antibody

What is PJA2 and what are its primary cellular functions?

PJA2 (praja ring finger 2) is an E3 ubiquitin-protein ligase that plays critical roles in protein stability and cellular signaling. Its primary functions include:

• Ubiquitination of cAMP-dependent protein kinase type I and II regulatory subunits, targeting them for proteasomal degradation

• Contribution to PKA-mediated long-term memory processes

• Regulation of TLR2 signaling pathway through ubiquitination of MFHAS1

• Role in ciliogenesis through ubiquitination of OFD1

• Negative regulation of type I interferon signaling via interaction with Janus kinases (TYK2 and JAK1)

What are the critical considerations when selecting a PJA2 antibody for research applications?

When selecting a PJA2 antibody, researchers should consider:

• Validated applications (WB, ICC/IF, IHC-P, IP, ELISA)

• Species reactivity (human, mouse, rat)

• Target epitope (antibodies target different regions of PJA2, such as aa 250-350 or aa 141-190)

• Clonality (polyclonal vs. monoclonal)

• Reported molecular weight detection (78 kDa calculated, but observed at 140-180 kDa in some applications)

• Validation data with appropriate positive controls (e.g., Jurkat cells, RT4 cells, U-251 MG cells)

How can I optimize Western blotting conditions for detecting PJA2?

Optimization of Western blotting for PJA2 detection requires:

• Appropriate sample selection (Jurkat, RT4, or U-251 MG cells serve as positive controls)

• Recommended antibody dilutions (typically 1:500-1:2000, but varies by manufacturer)

• Expected molecular weight discrepancy awareness (calculated MW: 78 kDa; observed MW: 140-180 kDa)

• Proper blocking buffers (5% BSA or 5% skim milk are recommended)

• Appropriate incubation times (overnight primary antibody incubation at 4°C)

What methodological considerations are important for immunoprecipitation (IP) experiments with PJA2?

For successful PJA2 immunoprecipitation:

• Use lysis buffer containing appropriate detergents and protease inhibitors (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 10 mM NaF, 1 mM sodium orthovanadate, and protease inhibitors)

• Incubate lysates overnight with antibody at 4°C

• Use protein A/G plus agarose beads for pull-down

• Include appropriate controls (IgG control, input control)

• Consider co-IP experiments to investigate PJA2 interactions with potential partners like JAK1, TYK2, or TCF/LEF1

• Validate interactions using reciprocal IP (e.g., IP with anti-PJA2 followed by western blot for interacting protein and vice versa)

How can PJA2 antibodies be employed to study its role in type I interferon signaling pathways?

To investigate PJA2's role in interferon signaling:

• Perform co-immunoprecipitation experiments using PJA2 antibodies to confirm interactions with TYK2 and JAK1

• Use reciprocal IP approaches (e.g., V5-tagged TYK2 can precipitate endogenous PJA2, while Flag-tagged PJA2 can precipitate endogenous TYK2)

• Assess PJA2's effect on ubiquitination of JAK1 and TYK2 through ubiquitination assays

• Employ siRNA-mediated depletion of PJA2 followed by assessment of IFN-α2-stimulated gene expression (e.g., ISG54, MX1) and antiviral activity

• Examine phosphorylation status of TYK2 and downstream STAT signaling in PJA2-depleted versus control cells

What approaches can be used to study PJA2's involvement in Wnt/β-catenin signaling and stem cell differentiation?

For investigating PJA2's role in Wnt signaling and stem cell biology:

• Utilize Wnt reporter luciferase assays with PJA2 overexpression or knockdown

• Examine protein dynamics of PJA2 and TCF/LEF1 during embryonic stem cell differentiation using Western blotting

• Perform co-immunoprecipitation to confirm interaction between PJA2 and TCF/LEF1

• Use ubiquitination assays to assess PJA2-mediated ubiquitination of TCF/LEF1

• Monitor effects of PJA2 manipulation on stem cell markers and differentiation processes

Research has demonstrated that PJA2 protein levels increase during mouse embryonic stem cell differentiation while TCF1, LEF1, and Oct4 levels decrease, suggesting an inverse relationship. PJA2 has been shown to interact with and enhance ubiquitination of TCF/LEF1, thereby inhibiting Wnt/β-catenin signaling .

How do I address discrepancies in observed molecular weight for PJA2 in Western blot experiments?

When encountering molecular weight discrepancies:

• Be aware that while the calculated molecular weight of PJA2 is 78 kDa, it is frequently observed at 140-180 kDa in Western blot applications

• Consider post-translational modifications (particularly ubiquitination) that may affect mobility

• Verify antibody specificity using positive controls (Jurkat, RT4, U-251 MG cells)

• Include multiple antibodies targeting different epitopes when possible

• Perform knockdown/knockout validation to confirm band specificity

• Consider the existence of alternatively spliced isoforms that may affect protein size

What are potential sources of variability in PJA2 detection across different experimental systems?

Variability sources may include:

• Cell type-specific expression levels and post-translational modifications

• Sample preparation methods (lysis buffers, denaturation conditions)

• Antibody epitope accessibility in different applications

• Cell-specific protein complexes that may mask epitopes

• Experimental conditions affecting PJA2 expression or localization (stimulation with cAMP, Wnt ligands, or interferons)

• Differences in antibody binding affinity between manufacturers

When comparing results across different experimental systems, it is advisable to use the same antibody clone and standardize protocols as much as possible .

How can I explore PJA2's role in neurodegenerative processes using antibody-based approaches?

To investigate PJA2's neurodegeneration connections:

• Use PJA2 antibodies for co-localization studies with AD markers in neuronal cell models

• Examine PJA2 levels in HT-22 cells or other neuronal models with overexpression or knockdown approaches

• Assess effects on AD marker genes (App, Mapt, Gsap) using qRT-PCR following PJA2 manipulation

• Investigate neurite outgrowth and cell proliferation using immunofluorescence in combination with PJA2 antibodies

• Study the P2rx3/P2rx7 axis in relation to PJA2 using co-immunoprecipitation and expression analysis

Research has shown that PJA2 overexpression in HT-22 cells inhibits the expression of AD marker genes (App, Mapt, Gsap) and promotes axonal outgrowth and cell proliferation. Conversely, PJA2 knockdown increases expression of these markers and reduces cell proliferation .

What methodological approaches can be used to study PJA2's E3 ligase activity and substrates beyond established targets?

For investigating novel PJA2 ubiquitination targets:

• Employ proximity labeling techniques (TurboID-based) coupled with affinity purification-mass spectrometry to identify proteins in close proximity to PJA2

• Perform ubiquitination assays with potential substrates using immunoprecipitation followed by ubiquitin immunoblotting

• Use proteomics approaches to identify differentially ubiquitinated proteins upon PJA2 manipulation

• Employ structure-function analysis with PJA2 mutants lacking E3 ligase activity to confirm direct enzymatic effects

• Consider the nature of ubiquitination (K48 vs. K63 linkages) to distinguish between degradative and non-degradative signaling roles

Recent research has employed TurboID-based proximity labeling to identify PJA2 as a negative regulator of type I interferon signaling through its interaction with JAK1 and TYK2, promoting their non-degradative ubiquitination .

How can I integrate multiple antibody-based techniques to comprehensively characterize PJA2 function in a specific cellular context?

An integrative approach should include:

• Initial characterization of PJA2 expression using Western blotting in your cell type of interest

• Subcellular localization studies using immunofluorescence to determine compartmentalization

• Co-immunoprecipitation to identify relevant binding partners in your specific context

• Functional assays following PJA2 manipulation (overexpression, knockdown)

• Ubiquitination assays to assess E3 ligase activity toward putative substrates

• Reporter assays to measure effects on relevant signaling pathways (Wnt, PKA, interferon)

What experimental considerations should be taken when studying the contradictory roles of PJA2 across different signaling pathways?

When investigating seemingly contradictory functions:

• Carefully control experimental conditions that might activate specific pathways

• Use pathway-specific inhibitors to isolate effects

• Consider tissue/cell type specificity of PJA2 functions

• Examine temporal dynamics of PJA2 activity in response to different stimuli

• Investigate potential co-factors that might direct PJA2 toward specific substrates

• Use domain-specific mutants to separate different PJA2 functions